1. Mahungu T, Ballinger J, Swaden L, et al.: Switching to Saquinavir 500/r-based regimens in subjects on HAART is not associated with loss of virologic control [abstract# PE1.1/5]. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17–20, 2005.
2. Awni W, Chiu Y-L, Zhu T, et al.: Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation [abstract# We0206]. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24–27, 2005.
3. Geleziunas R, Gallagher K, Zhang H, et al.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′-dideoxy-2′,3′-didehydro-5-.uorocytidine (Reverset). Antivir Chem Chemo 2003, 14:49–59.
4. Hammond JL, Parikh UM, Koontz DL, et al.: In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2′,3′-didehydro-2′,3′-dideoxy-5-.uorocytidine. Antimicrob Agents Chemother 2005, 49:3930–3932.
5. Murphy RL, Schürmann D, Kravec I, et al.: Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients [abstract# 545]. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–17, 2003.